Arovella Therapeutics has obtained an exclusive global license for a novel armouring cytokine technology for CAR-iNKT cell platforms from the University of North Carolina Lineberger Comprehensive Cancer Center.
The technology enhances CAR-iNKT cell performance within solid tumours by leading to a ten-fold increase in circulating CAR-iNKT numbers in animal models and significantly improving anti-tumour activity and overall survival.
The license makes Arovella the exclusive global developer of IL-12-TM armoured CAR-iNKT cells.